OncoMatch/Clinical Trials/NCT07341360
Pseudovax - A Cancer Vaccine for Patients With Pseudomyxoma Peritonei
Is NCT07341360 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies multiple treatments including Molgramostim and Tislelizumab for pseudomyxoma peritonei.
Treatment: Molgramostim · Tislelizumab — Participants will receive vaccination with Pseudovax/GM-CSF in combination with PD-1 inhibitor tislelizumab over a period of up to two years. The vaccine is expected to reactivate measurable immune response, and tislelizumab to restore anticancer immunity in patients with GNAS mutated pseudomyxoma peritonei.
Check if I qualifyExtracted eligibility criteria
Biomarker criteria
Required: GNAS mutation
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: blood transfusion or growth factor support
Blood transfusion or growth factor support ≤ 14 days before sample collection at screening
Cannot have received: interventional therapy
Subject has within the last 30 days received any other interventional therapy that, in the opinion of the Investigator, could influence the outcome of this study
Cannot have received: therapeutic oral or intravenous antibiotics
Therapeutic oral or intravenous antibiotics within 2 weeks before first dose of IMP
Cannot have received: major surgical procedure requiring general anesthesia
Any major surgical procedure requiring general anesthesia ≤ 28 days before first dose of IMP
Cannot have received: allogeneic stem cell transplantation or organ transplantation
Prior allogeneic stem cell transplantation or organ transplantation
Lab requirements
Blood counts
Absolute neutrophil count: ≥ 1.5 x10^9/L; Platelets: ≥ 100 x10^9/L; Hemoglobin: ≥ 9 x10^9/L; INR ≤ 1.5 ULN and aPTT ≤ 1.5 ULN unless subject is receiving anticoagulant therapy
Kidney function
Creatinine ≤ 1.5 ULN OR measured/calculated GFR ≥60 mL/min; Albumin ≥ 30 g/L
Liver function
Total bilirubin ≤ 1.5 ULN; ASAT and ALAT ≤ 3 ULN
Adequate organ, bone marrow, liver, and renal function at screening, including: Absolute neutrophil count: ≥ 1.5 x10^9/L; Platelets: ≥ 100 x10^9/L; Hemoglobin: ≥ 9 x10^9/L; Creatinine ≤ 1.5 ULN OR measured/calculated GFR ≥60 mL/min; Albumin ≥ 30 g/L; Total bilirubin ≤ 1.5 ULN; ASAT and ALAT ≤ 3 ULN; INR ≤ 1.5 ULN and aPTT ≤ 1.5 ULN unless subject is receiving anticoagulant therapy.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify